quinazolines has been researched along with quazinone in 18 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 10 (55.56) | 18.7374 |
| 1990's | 4 (22.22) | 18.2507 |
| 2000's | 3 (16.67) | 29.6817 |
| 2010's | 1 (5.56) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Braunwald, E; Colucci, WS; Wright, RF | 1 |
| Komajda, M | 1 |
| Chatterjee, K; Daly, PA; Kereiakes, D; Modin, G; Simonton, CA | 1 |
| Elkik, F; Grosgogeat, Y; Komajda, M; Lechat, P | 1 |
| Braun, S; Laniado, S; Shargorodsky, B; Talit, U | 1 |
| Ferguson, JJ; Grossman, W; McKay, RG; Miller, MJ; Momomura, S; Pasternak, RC; Sahagian, P | 1 |
| Anderson, S; Chatterjee, K; Curran, D; Daly, PA; Parmley, WW; Scheinbaum, M; Viquerat, CE | 1 |
| Alfiero, R; Cocco, G; Padula, A; Rizzo, A; Strozzi, C; Tasini, MT; Urso, L | 1 |
| Cocco, G; Sfrisi, C | 1 |
| Haefelfinger, P; Hess, B | 1 |
| Forssmann, WG; Jonas, U; Meyer, M; Schulz-Knappe, P; Stief, CG; Taher, A; Truss, M | 1 |
| Becker, AJ; Forssmann, WG; Jonas, U; Meyer, M; Schulz-Knappe, P; Stief, CG; Taher, A; Truss, M; Uckert, S | 1 |
| Forssmann, WG; Jonas, U; Meyer, M; Stief, CG; Taher, A | 1 |
| Horiuchi, M; Mita, S; Oki, K; Senda, T; Tsuji, F | 1 |
| Bischoff, E; Jonas, U; Kühn, R; Lietz, B; Schramm, M; Stief, CG; Truss, MC; Uckert, S | 1 |
| Casadei, B; Musialek, P; Paterson, DJ; Rigg, L; Terrar, DA | 1 |
| Dhar, S; Fryknäs, M; Gullbo, J; Gustafsson, MG; Isaksson, A; Larsson, R; Lövborg, H; Nygren, P; Rickardson, L; Wickström, M | 1 |
| Andersson, C; Blom, K; Edqvist, PH; Fryknäs, M; Gustafsson, MG; Jarvius, M; Larsson, R; Nazir, M; Nyberg, F; Nygren, P; Senkowski, W | 1 |
3 review(s) available for quinazolines and quazinone
| Article | Year |
|---|---|
New positive inotropic agents in the treatment of congestive heart failure. Mechanisms of action and recent clinical developments. 2.
Topics: 3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester; Administration, Oral; Aminopyridines; Amrinone; Cardiotonic Agents; Coenzymes; Enoximone; Heart; Heart Failure; Hemodynamics; Humans; Imidazoles; Injections, Intravenous; Milrinone; Nifedipine; Oxyfedrine; Phosphodiesterase Inhibitors; Pyridazines; Pyridones; Quinazolines; Ubiquinone | 1986 |
[Old and new positive inotropic drugs: problems and controversies].
Topics: Adrenergic alpha-Agonists; Adrenergic beta-Agonists; Aminopyridines; Amrinone; Cardiotonic Agents; Glucagon; Glucosides; Heart Failure; Histamine; Humans; Imidazoles; Inosine; Quinazolines; Xanthines | 1984 |
[Positive inotropic therapy of cardiac failure: old and new drugs, controversies and tests].
Topics: Aminopyridines; Amrinone; Cardiac Glycosides; Cardiotonic Agents; Glucagon; Heart Failure; Histamine; Humans; Imidazoles; Inosine; Phosphodiesterase Inhibitors; Quinazolines; Sympathomimetics | 1984 |
1 trial(s) available for quinazolines and quazinone
| Article | Year |
|---|---|
RO 13-6438 in congestive heart failure: dose-response relationship after 3 single doses.
Topics: Administration, Oral; Aged; Aged, 80 and over; Cardiotonic Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Tolerance; Female; Heart Failure; Hemodynamics; Humans; Lung; Male; Middle Aged; Quinazolines; Vascular Resistance | 1987 |
14 other study(ies) available for quinazolines and quazinone
| Article | Year |
|---|---|
[New cardiotonic agents].
Topics: Aminopyridines; Amrinone; Cardiotonic Agents; Colforsin; Deoxyepinephrine; Humans; Imidazoles; Levodopa; Milrinone; Practolol; Prenalterol; Propanolamines; Pyridones; Quinazolines; Xamoterol | 1985 |
Survival in severe left ventricular failure treated with the new nonglycosidic, nonsympathomimetic oral inotropic agents.
Topics: Administration, Oral; Aged; Anti-Arrhythmia Agents; Cardiotonic Agents; Death, Sudden; Drug Evaluation; Enoximone; Female; Heart Failure; Humans; Imidazoles; Male; Middle Aged; Milrinone; Pyridones; Quinazolines; Retrospective Studies; Time Factors | 1987 |
Haemodynamic effects of Ro 13-6438, a new inotropic agent with vasodilating properties.
Topics: Animals; Dogs; Drug Evaluation, Preclinical; Female; Hemodynamics; Male; Myocardial Contraction; Quinazolines; Stimulation, Chemical; Vasodilator Agents | 1986 |
Assessment of left ventricular end-systolic pressure-volume relations with an impedance catheter and transient inferior vena cava occlusion: use of this system in the evaluation of the cardiotonic effects of dobutamine, milrinone, Posicor and epinephrine.
Topics: Animals; Blood Pressure; Cardiography, Impedance; Cardiotonic Agents; Constriction; Dobutamine; Dogs; Drug Evaluation, Preclinical; Epinephrine; Heart Rate; Milrinone; Myocardial Contraction; Pyridones; Quinazolines; Stroke Volume; Swine; Vena Cava, Inferior | 1986 |
RO13-6438, a new inotrope-vasodilator: systemic and coronary hemodynamic effects in congestive heart failure.
Topics: Adult; Aged; Blood Pressure; Cardiotonic Agents; Coronary Circulation; Female; Heart Failure; Heart Rate; Hemodynamics; Humans; Male; Middle Aged; Myocardium; Norepinephrine; Oxygen Consumption; Quinazolines; Vasodilator Agents | 1985 |
Determination of the imidazo quinazoline derivative Ro 13-6438 in biological fluids by high-performance liquid chromatography.
Topics: Chromatography, High Pressure Liquid; Humans; Quinazolines; Temperature; Time Factors | 1984 |
Characterization of cyclic nucleotide phosphodiesterase isoenzymes in the human ureter and their functional role in vitro.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Calmodulin; Chromatography, DEAE-Cellulose; Cyclic AMP; Cyclic GMP; Dose-Response Relationship, Drug; Humans; Hydrolysis; In Vitro Techniques; Muscle Relaxation; Muscle Tonus; Muscle, Smooth; Papaverine; Phosphodiesterase Inhibitors; Purinones; Pyrrolidinones; Quinazolines; Rolipram; Ureter | 1994 |
Phosphodiesterase isoenzymes in human ureteral smooth muscle: identification, characterization, and functional effects of various phosphodiesterase inhibitors in vitro.
Topics: Chromatography, Ion Exchange; Cyclic AMP; Cyclic GMP; Dose-Response Relationship, Drug; Humans; Hydrolysis; In Vitro Techniques; Isoenzymes; Muscle Contraction; Muscle, Smooth; Papaverine; Phosphodiesterase Inhibitors; Phosphoric Diester Hydrolases; Purinones; Pyrrolidinones; Quinazolines; Rolipram; Ureter | 1995 |
Cyclic nucleotide phosphodiesterase in human cavernous smooth muscle.
Topics: Animals; Cyclic AMP; Cyclic GMP; Humans; In Vitro Techniques; Isoenzymes; Male; Muscle, Smooth; Papaverine; Penile Erection; Penis; Phosphodiesterase Inhibitors; Phosphoric Diester Hydrolases; Purinones; Pyrrolidinones; Quinazolines; Rolipram | 1997 |
Effects of mitogen-activated protein kinase inhibitors or phosphodiesterase inhibitors on interleukin-1-induced cytokines production in synovium-derived cells.
Topics: 4-(3-Butoxy-4-methoxybenzyl)-2-imidazolidinone; Calcium-Calmodulin-Dependent Protein Kinases; Cytokines; Dose-Response Relationship, Drug; Humans; Imidazoles; Interleukin-1; Phosphodiesterase Inhibitors; Pyridines; Pyrrolidinones; Quinazolines; Rolipram; Synovial Membrane | 1999 |
Relaxation of human ureteral smooth muscle in vitro by modulation of cyclic nucleotide-dependent pathways.
Topics: Colforsin; Cyclic AMP; Cyclic GMP; Humans; In Vitro Techniques; Isoquinolines; Muscle, Smooth; Nitroprusside; Phosphodiesterase Inhibitors; Phosphoric Diester Hydrolases; Piperidines; Platelet Aggregation Inhibitors; Potassium Chloride; Purinones; Quinazolines; Rolipram; Tetrahydroisoquinolines; Ureter; Vasodilator Agents | 2000 |
Role of cGMP-inhibited phosphodiesterase and sarcoplasmic calcium in mediating the increase in basal heart rate with nitric oxide donors.
Topics: Animals; Calcium; Carbazoles; Cyclic AMP-Dependent Protein Kinases; Cyclic GMP; Cyclic GMP-Dependent Protein Kinases; Dose-Response Relationship, Drug; Enzyme Inhibitors; Guinea Pigs; Heart Atria; Heart Rate; Hydrazines; Indoles; Isoquinolines; Male; Milrinone; Models, Biological; Molsidomine; Nitric Oxide Donors; Nitrogen Oxides; Phosphodiesterase Inhibitors; Phosphoric Diester Hydrolases; Platelet Aggregation Inhibitors; Pyrroles; Quinazolines; Ryanodine; Sarcoplasmic Reticulum; Signal Transduction; Spectrometry, Fluorescence; Sulfonamides; Superoxide Dismutase; Tetrahydroisoquinolines; Thionucleotides; Time Factors; Vasodilator Agents | 2000 |
Phenotype-based screening of mechanistically annotated compounds in combination with gene expression and pathway analysis identifies candidate drug targets in a human squamous carcinoma cell model.
Topics: Carcinoma, Squamous Cell; Caspases; Combinatorial Chemistry Techniques; Drug Evaluation, Preclinical; Electronic Data Processing; Gene Expression Profiling; HeLa Cells; Humans; Models, Biological; Oligonucleotide Array Sequence Analysis; Phenotype; Phosphodiesterase Inhibitors; Phosphoric Diester Hydrolases; Pyridazines; Quinazolines; RNA, Messenger; Signal Transduction | 2006 |
Targeting tumor cells based on Phosphodiesterase 3A expression.
Topics: Adult; Aged; Antineoplastic Agents; Biomarkers, Tumor; Carrier Proteins; Cell Line, Tumor; Colonic Neoplasms; Cyclic Nucleotide Phosphodiesterases, Type 3; Female; Gastrointestinal Stromal Tumors; Gene Expression; Humans; Lung Neoplasms; Male; Melanoma; Middle Aged; Molecular Targeted Therapy; Neoplasm Proteins; Organ Specificity; Organoplatinum Compounds; Oxaliplatin; Phosphodiesterase Inhibitors; Pyridazines; Quinazolines; RNA, Messenger; Skin Neoplasms | 2017 |